文献速递慢性静脉疾病

深静脉反流治疗器械、设计与试验的系统综述

Systematic Review of Devices, Designs, and Trials for the Treatment of Deep Venous Reflux.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2026-10-19

该系统综述纳入15项研究(8项人体、7项动物),评估治疗深静脉反流的假体或生物假体装置。人体研究技术成功率87.7%-100%,通畅率67%-100%,但瓣膜功能评估异质性大,解剖、血流动力学与临床结局常不一致。血栓风险、瓣膜功能改善有限及终点未标准化是监管批准的主要障碍。

要点

  • 深静脉反流装置人体研究技术成功率高,但瓣膜 competency 报告范围0%-92%,评估方法差异大。
  • 术后1年疼痛改善75%-97%,rVCSS下降37%-81%,但不足半数患者达到预设反流减少终点。
  • 瓣膜血栓和闭塞风险突出,动物植入闭塞率高达28%,人体部分队列18%-22%。

核心结论

  • 多种深静脉反流装置显示技术可行性和症状改善,但血栓风险、瓣膜功能改善有限及终点未标准化阻碍监管批准。
  • 需建立整合客观血流动力学指标与患者中心结局的标准化复合终点以推进器械研发和临床转化。

研究设计与样本

  • PROSPERO注册系统综述(CRD420251101761),检索6个数据库至2026年2月。
  • 纳入15项研究:8项人体研究和7项动物研究,评估假体或生物假体深静脉反流装置。
  • 排除原生瓣膜修复或自体移植研究;人体研究主要结局为临床改善。

主要发现

  • 516条记录中15项符合纳入标准;两种主要策略为腔内瓣膜修复和外加压,约40%装置经皮或经静脉递送。
  • 人体研究技术成功率87.7%-100%,通畅率67%-100%,围术期并发症率0%-44%(出血、伤口感染、瓣膜血栓)。
  • 瓣膜闭塞在动物植入中高达28%,在部分人体队列中为18%-22%;动物研究有2例围术期死亡,人体研究无报告。
  • 人体研究瓣膜 competency 范围0%-92%,反映影像模态和定义异质性;解剖通畅、双功超声反流减少与临床改善常不一致。
  • 当代多中心试验中不足半数患者达到预设反流减少终点;1年时疼痛改善75%-97%,rVCSS下降37%-81%,临床有意义改善(≥3分)达84.6%,溃疡愈合67%-100%。

关键数值与推荐

  • 人体研究技术成功率87.7%-100%,通畅率67%-100%,围术期并发症率0%-44%。
  • 瓣膜闭塞动物植入高达28%,人体部分队列18%-22%;瓣膜 competency 报告范围0%-92%。
  • 1年疼痛改善75%-97%,rVCSS下降37%-81%,临床有意义改善(≥3分)达84.6%,溃疡愈合67%-100%。
  • 随访延长至动物研究2年、人体系列最长11年,报告结局各异。

临床怎么用

  • 现有深静脉反流装置可改善症状,但需警惕瓣膜血栓和闭塞风险。
  • 解读疗效时应综合解剖通畅、血流动力学和患者报告结局,避免单一指标误判。
  • 未来试验应采用标准化复合终点以支持监管评估和临床决策。

局限性

  • 纳入研究数量有限(15项),人体与动物研究混合,异质性大。
  • 瓣膜功能评估方法和定义不统一,结局报告不一致。
  • 缺乏标准化终点,限制跨研究比较和监管转化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Chronic venous insufficiency (CVI) is driven primarily by venous reflux and affects nearly one-third of adults. While superficial reflux is effectively treated with ablation, therapeutic options for deep venous reflux (DVR) remain limited. Despite decades of innovation, no prosthetic or bioprosthetic venous valve has achieved U.S. regulatory approval. We systematically reviewed device strategies, clinical and hemodynamic outcomes, complications, and barriers to translation for devices designed to treat DVR. METHODS: We conducted a PROSPERO-registered systematic review (CRD420251101761) of six databases from inception through February 2026, including in vivo animal and human studies evaluating prosthetic or bioprosthetic devices for DVR. Studies of native valve repair or autotransplantation were excluded. The primary outcome for human studies was clinical improvement, and secondary outcomes included patency, procedural complications, valvular function, and thrombosis. RESULTS: Of 516 records identified, 15 met inclusion criteria: 8 human and 7 animal studies. Two principal strategies were identified: intraluminal valve restoration (VR) and external compression (EC), with approximately 40% of devices delivered percutaneously or endovenously. In human studies, technical success ranged from 87.7%-100%, patency from 67%-100%, and perioperative complication rates from 0%-44%, consisting primarily of bleeding, wound infection, and valve thrombosis. Valve occlusion occurred in up to 28% of animal implants and 18%-22% of select human cohorts. Two perioperative deaths occurred in animal studies; none were reported in human studies. Among human studies, valve competency assessment methods varied substantially. Reported competency ranged from 0%-92%, reflecting heterogeneity in imaging modalities and definitions. Discordance between anatomic patency, duplex-derived reflux reduction, and clinical improvement was frequently observed. In contemporary multicenter trial data, fewer than half of patients met predefined reflux-reduction endpoints despite high device patency and substantial clinical improvement, highlighting discordance between anatomic, hemodynamic, and patient-centered outcomes. By one year, pain had improved in 75%-97% of patients; rVCSS decreased by 37%-81%, with clinically meaningful (≥3-point) improvement in up to 84.6%; and ulcer healing ranged from 67%-100%. Longer follow-up extended to 2 years in animal studies and up to 11 years in human series with various outcomes reported. CONCLUSION: Several devices developed for DVR have demonstrated technical feasibility and symptom improvement. However, the risk of thrombosis, the marginal impact on valvular function, and the lack of standardization and selection of adequate endpoints in the measurement of results remain major barriers to regulatory approval. Standardized composite endpoints integrating objective hemodynamic measures with patient-centered outcomes are essential to advance durable DVR device development and clinical translation.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Ofori KA, Li S, Grimshaw AA, et al. Systematic Review of Devices, Designs, and Trials for the Treatment of Deep Venous Reflux. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 42896733. doi:10.1016/j.jvsv.2026.102643

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。